GlassScriptPhysician profile
Kenneth Marvin
NPI 1417035221
$416.56
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $211 · 2020: $157 · 2021: $20.44 · 2022: $27.45.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $76.68 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $65.87 | 2019 | |
| Amarin Pharma, INC. | $62.30 | 2019-2020 | |
| Bardy Diagnostics, INC. | $47.89 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $31.47 | 2020 | |
| Boston Scientific Corporation | $30.56 | 2020 | |
| Sanofi-Aventis U.S. LLC | $29.12 | 2019 | |
| Philips North America LLC | $23.41 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $23.10 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $13.74 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $12.42 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kenneth Marvin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.